<DOC>
	<DOCNO>NCT02012166</DOCNO>
	<brief_summary>This study ass pharmacokinetics , safety , tolerability sequential single oral dos MK-8093 10 mg , 40 mg , 200 mg , placebo MK-8093 ( Part 1 ) depend treatment assignment young healthy male participant . In Part 2 study , sequential single oral dos MK-8093 200 mg , 1000 mg placebo MK-8093 depend treatment assignment evaluate . The primary hypothesis study least one dose MK-0893 produce great reduction glucagon-induced glycemia compare placebo follow infusion glucagon , Sandostatine® , basal insulin .</brief_summary>
	<brief_title>A Study MK-0893 Glucagon-Induced Glycemic Excursion Healthy Male Participants Following Intravenous Administration Glucagon , Sandostatine® Insulin ( MK-0893-002 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Good health Body Mass Index 18 28 kg/m^2 , 30 kg/m^2 approval sponsor Nonsmoker least 6 month Willing avoid strenuous physical activity Willing avoid alcohol , caffeine , grapefruit juice consumption History renal , neurologic , gastrointestinal respiratory disease gastrointestinal surgery History multiple and/or severe allergy prescription , nonprescription investigational drug food History cardiovascular/cardiac disease History hepatic disease primary biliary cirrhosis History hypoglycemia glucose intolerance , type 1 diabetes , type 2 diabetes Requires anticipate use prescription nonprescription medication , include herbal remedy A user illicit drug history drug alcohol abuse Surgery , donate unit blood , participate another clinical study within 4 week prior study participation History hypersensitivity insulin , glucagon , Sandostatine® .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Physiological Effects Drugs</keyword>
</DOC>